Delving into the Latest Updates on HAL-MPE1 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Peanut allergy vaccine, Peanut extract

+ [1]

Target-

Action

modulators

Mechanism

Immunomodulators

Therapeutic Areas

Immune System Diseases

Active Indication-

Inactive Indication

Peanut Hypersensitivity

Originator Organization

HAL Allergy Holding BV

Active Organization-

Inactive Organization

HAL Allergy Holding BV

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Currently, there is no effective causal treatment for peanut allergy. A chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed. Results from in vitro and in vivo preclinical studies demonstrate the immunotherapeutic potential of HAL-MPE1. Therefore, a phase I, single-centre clinical trial has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic patients.

Start Date01 Jun 2014

Sponsor / Collaborator

HAL Allergy Holding BV

100 Clinical Results associated with HAL-MPE1

Login to view more data

100 Translational Medicine associated with HAL-MPE1

Login to view more data

100 Patents (Medical) associated with HAL-MPE1

Login to view more data

11

Literatures (Medical) associated with HAL-MPE1

01 Nov 1984·The Indian journal of medical research

Chemical & nutritional studies on Acacia auriculaeformis seed oil.

Article

Author: Majumdar, S G ; Maity, C R ; Mandal, B

01 Jun 1982·The Indian journal of medical research

Effect of composition of diet on some aspects of cholesterol and triglyceride metabolism in rats.

Article

Author: Premakumari, K ; Vijayammal, P L ; Kurup, P A ; Leelamma, S

01 Dec 1980·Indian journal of experimental biology

Studies on fatty acid composition of serum lipids in rats red mustard oil of groundnut oil containing diets.

Article

Author: Talukder, G ; Ray, S ; Sengupta, K P ; Chatterjee, G C

100 Deals associated with HAL-MPE1

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peanut Hypersensitivity	Phase 1	Denmark	HAL Allergy Holding BV	01 Jun 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAAAI2017 Manual	Phase 1	Peanut Hypersensitivity	17	HAL-MPE1	(wtfcskmgfq) = Early and late local reactions were more frequently observed after HAL-MPE1 compared to placebo, were generally of mild intensity and mainly consisted of redness and no wheal sizes exceeding 5 cm were recorded. Early systemic reactions were only observed in the active treatment group. decsnmkrkf (jzxxxtasdp ) View more	Positive	01 Feb 2017
				placebo
AAAAI2005	Not Applicable	Hypersensitivity Ara h 2 \| IgE	-	peanut extracts (Crude peanut extract (CPE))	ursryazebr(rcabwsknef) = dmvqampnjt nbrkulhytd (qyootmoajm )	Positive	19 Mar 2005
				peanut extracts (Depleted crude peanut extract (CPE))	ursryazebr(rcabwsknef) = omhesrzqrg nbrkulhytd (qyootmoajm )